“Lyophilization in Pharmaceuticals market set to grow to $9.2bn by 2024” says new Visiongain report

28 March 2019
Pharma

Visiongain has published a new pharma report Lyophilization in Pharmaceuticals Market Forecast 2019-2029: Food Processing and Packaging, Pharmaceutical and Biotechnology, Medical Application, Industrial-scale, Pilot-scale, Laboratory-scale, Tray-style Freeze Dryers, Manifold Freeze Dryers, Shell Freeze Dryers, Loading & Unloading Systems, Controlling & Monitoring Systems, Vacuum Systems, Clean-In-Place (CIP) Systems, Drying Chambers, Freeze Drying Trays & Shelves, Manifolds, Other Accessories.

The global lyophilization in pharmaceuticals market is estimated to have reached $5.6bn in 2018. The pharmaceutical and biotechnology segment held 33% of the lyophilization market in 2018.

Pharmaceutical and biotechnology drugs are often highly sensitive and complex molecules that can be negatively affected by external factors such as sunlight, oxygen, pH and others. Leaving marketers and manufacturers looking for an innovative way to preserve and protect these difficult-to-handle substances, lyophilization offers a highly efficient and suitable technique to meet the needs for handling the complexities of constituents during pharmaceutical manufacturing.

The lead analyst commented that "Lyophilization in pharmaceuticals and biotechnology is growing at a rapid pace due to the high safety and sterility offered by freeze-dried injectables, mainly in the case of unstable proteins that are highly susceptible to chemical and physical disintegration and changes.

The lyophilization market includes a large number of small and medium-sized companies and stable innovative activity. End-users have the opportunity to choose from a number of suppliers. External forces have a significant effect on this industry, such as government involvement regulatory agencies and reimbursement policies. On a global level, we can expect growth in this market, especially in the emerging economies."

Leading companies featured in this report include Azbil Corporation, Biophama process Systems, Inc., GEA Group, Labconco Corporation, Millrock Technology, Inc.and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever